Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy
Catherine J. Lee(University of Utah), Daniel R. Couriel(The University of Texas MD Anderson Cancer Center), Nosha Farhadfar(University of Florida Health), Yoshihiro Inamoto, Sager Patel(University of Utah), Peiman Hematti(UW Health University Hospital), Zachariah DeFilipp(Harvard University), Hasan Hashem(Nationwide Children's Hospital), Shahrukh K. Hashmi(Mayo Clinic), Sanghee Hong(Cleveland Clinic), Jean‐Yves Cahn, Neel S. Bhatt(The Ohio State University Wexner Medical Center), Nasheed Hossain(Loyola University Chicago), Vijaya Raj Bhatt(Susan Thompson Buffett Foundation), Mukta Arora(Fairview Health Services), Stephen R. Spellman(National Marrow Donor Program), Sherif M. Badawy(Northwestern University), Ruta Brazauskas(Medical College of Wisconsin), Akshay Sharma(St. Jude Children's Research Hospital), Carrie L. Kitko(Vanderbilt University Medical Center), Shahinaz M. Gadalla(Division of Cancer Epidemiology and Genetics), Lazaros J. Lekakis(University of Miami Hospital), Jeffery J. Auletta(Nationwide Children's Hospital), Dipenkumar Modi(Wayne State University), Robert Peter Gale(Imperial College London), Tao Wang(Medical College of Wisconsin), Miguel Ángel Díaz(Hospital Infantil Universitario Niño Jesús), Karen Chen(Medical College of Wisconsin), Scott R. Solomon(Northside Hospital), Joseph A. Pidala(Moffitt Cancer Center), Margaret L. MacMillan(University of Minnesota Medical Center)
Cited by 18
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782